Published in Ann Transl Med on January 01, 2017
Hepatocyte Growth Factor/c-Met Signaling in Head and Neck Cancer and Implications for Treatment. Cancers (Basel) (2017) 0.75
Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature (2008) 75.40
Comprehensive molecular profiling of lung adenocarcinoma. Nature (2014) 11.02
Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet (1997) 6.83
Targeting MET in cancer: rationale and progress. Nat Rev Cancer (2012) 6.43
Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature (1984) 5.85
Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol (2013) 5.21
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med (2015) 4.24
Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res (2005) 4.13
The transcriptional landscape and mutational profile of lung adenocarcinoma. Genome Res (2012) 3.80
c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res (2003) 3.39
Somatic mutations lead to an oncogenic deletion of met in lung cancer. Cancer Res (2006) 3.12
Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene (1999) 3.01
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med (2015) 3.00
Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol (2011) 2.69
Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol (2012) 2.61
The connection between splicing and cancer. J Cell Sci (2006) 2.56
The Met tyrosine kinase receptor in development and cancer. Cancer Metastasis Rev (2008) 2.41
Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proc Natl Acad Sci U S A (2001) 2.38
A novel germ line juxtamembrane Met mutation in human gastric cancer. Oncogene (2000) 2.35
Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein. Mol Cell (2001) 2.26
C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu. Int J Cancer (2005) 2.25
Escape from Cbl-mediated downregulation: a recurrent theme for oncogenic deregulation of receptor tyrosine kinases. Cancer Cell (2003) 2.24
Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence. Cancer Discov (2011) 2.22
MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non-Small Cell Lung Carcinoma with Poor Prognosis. Clin Cancer Res (2016) 2.19
Expression and mutational analysis of MET in human solid cancers. Genes Chromosomes Cancer (2008) 2.06
An overview of the c-MET signaling pathway. Ther Adv Med Oncol (2011) 1.95
Hepatocyte growth factor/scatter factor-Met signaling in tumorigenicity and invasion/metastasis. J Mol Med (Berl) (1996) 1.91
Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. Cancer Discov (2015) 1.91
Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers. J Thorac Oncol (2009) 1.81
MET is a potential target across all papillary renal cell carcinomas: result from a large molecular study of pRCC with CGH array and matching gene expression array. Clin Cancer Res (2014) 1.71
Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer Discov (2015) 1.67
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol (2016) 1.67
Impact of MET amplification on gastric cancer: possible roles as a novel prognostic marker and a potential therapeutic target. Oncol Rep (2011) 1.66
Overexpression of the c-MET/HGF receptor gene in human thyroid carcinomas. Oncogene (1992) 1.51
Expression of the c-Met/HGF receptor in human breast carcinoma: correlation with tumor progression. Int J Cancer (1997) 1.48
Genetic and structural variation in the gastric cancer kinome revealed through targeted deep sequencing. Cancer Res (2010) 1.41
The TPR-MET oncogenic rearrangement is present and expressed in human gastric carcinoma and precursor lesions. Proc Natl Acad Sci U S A (1991) 1.40
MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome. Br J Cancer (2012) 1.39
RNA-seq of 272 gliomas revealed a novel, recurrent PTPRZ1-MET fusion transcript in secondary glioblastomas. Genome Res (2014) 1.34
Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer. Cancer Sci (2008) 1.31
Hepatocyte growth factor receptor, matrix metalloproteinase-11, tissue inhibitor of metalloproteinase-1, and fibronectin are up-regulated in papillary thyroid carcinoma: a cDNA and tissue microarray study. Clin Cancer Res (2003) 1.31
MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression. J Clin Oncol (2016) 1.27
Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations. J Clin Oncol (2015) 1.26
MET as a possible target for non-small-cell lung cancer. J Clin Oncol (2013) 1.25
The "lazarus response" in treatment-naive, poor performance status patients with non-small-cell lung cancer and epidermal growth factor receptor mutation. J Clin Oncol (2009) 1.21
Gastric cancer cell line Hs746T harbors a splice site mutation of c-Met causing juxtamembrane domain deletion. Biochem Biophys Res Commun (2010) 1.19
Hepatocyte growth factor/c-Met signaling promotes the progression of experimental human neuroblastomas. Cancer Res (2004) 1.18
A conserved DpYR motif in the juxtamembrane domain of the Met receptor family forms an atypical c-Cbl/Cbl-b tyrosine kinase binding domain binding site required for suppression of oncogenic activation. J Biol Chem (2004) 1.17
MET signaling pathway: a rational target for cancer therapy. J Clin Oncol (2011) 1.17
Mutation of juxtamembrane tyrosine residue 1001 suppresses loss-of-function mutations of the met receptor in epithelial cells. Proc Natl Acad Sci U S A (1995) 1.13
MET signaling: novel targeted inhibition and its clinical development in lung cancer. J Thorac Oncol (2012) 1.11
The Met oncogene and basal-like breast cancer: another culprit to watch out for? Breast Cancer Res (2010) 1.08
The Met receptor tyrosine kinase: a key player in oncogenesis and drug resistance. Pharmacol Ther (2013) 1.07
MET receptor tyrosine kinase sequence alterations in differentiated thyroid carcinoma. Am J Surg Pathol (2005) 1.06
Point mutations in the dystrophin gene: evidence for frequent use of cryptic splice sites as a result of splicing defects. Hum Mutat (1999) 1.03
PHA665752, a small-molecule inhibitor of c-Met, inhibits hepatocyte growth factor-stimulated migration and proliferation of c-Met-positive neuroblastoma cells. BMC Cancer (2009) 1.03
Gastrointestinal malignancies harbor actionable MET exon 14 deletions. Oncotarget (2015) 1.00
Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation. Lung Cancer (2015) 0.98
Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1. J Clin Oncol (2016) 0.95
Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations. J Thorac Oncol (2016) 0.95
Cabozantinib (XL184) Inhibits Growth and Invasion of Preclinical TNBC Models. Clin Cancer Res (2015) 0.94
Response to Crizotinib in a Patient With Lung Adenocarcinoma Harboring a MET Splice Site Mutation. Clin Lung Cancer (2015) 0.93
Analysis of MET genetic aberrations in patients with breast cancer at MD Anderson Phase I unit. Clin Breast Cancer (2014) 0.92
Randomized, phase II, placebo-controlled trial of onartuzumab and/or bevacizumab in combination with weekly paclitaxel in patients with metastatic triple-negative breast cancer. Ann Oncol (2015) 0.92
Identification of a novel type of alternative splicing of a tyrosine kinase receptor. Juxtamembrane deletion of the c-met protein kinase C serine phosphorylation regulatory site. J Biol Chem (1994) 0.90
The clinical and functional significance of c-Met in breast cancer: a review. Breast Cancer Res (2015) 0.89
Mutation and expression analyses of the MET and CDKN2A genes in rhabdomyosarcoma with emphasis on MET overexpression. Genes Chromosomes Cancer (2007) 0.88
MET Mutation Associated with Responsiveness to Crizotinib. J Thorac Oncol (2015) 0.87
An alternatively spliced form of Met receptor is tumorigenic. Exp Mol Med (2006) 0.86
MET-Mutated NSCLC with Major Response to Crizotinib. J Thorac Oncol (2015) 0.86
Identification of MET genomic amplification, protein expression and alternative splice isoforms in neuroblastomas. J Clin Pathol (2013) 0.85
The novel kinase inhibitor EMD1214063 is effective against neuroblastoma. Invest New Drugs (2014) 0.84
MET 14 Deletion in Sarcomatoid Non-Small-Cell Lung Cancer Detected by Next-Generation Sequencing and Successfully Treated with a MET Inhibitor. J Thorac Oncol (2015) 0.82
Identification of a novel MET mutation in high-grade glioma resulting in an auto-active intracellular protein. Acta Neuropathol (2015) 0.82
Understanding and Targeting MET Signaling in Solid Tumors - Are We There Yet? J Cancer (2016) 0.79
Lazarus-Type Response to Crizotinib in a Patient with Poor Performance Status and Advanced MET Exon 14 Skipping Mutation-Positive Lung Adenocarcinoma. J Thorac Oncol (2016) 0.79
Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer. Breast Cancer Res Treat (2016) 0.79
Gene of the month: HGF. J Clin Pathol (2016) 0.78
Met in urological cancers. Cancers (Basel) (2014) 0.77
A never-smoker lung adenocarcinoma patient with a MET exon 14 mutation (D1028N) and a rapid partial response after crizotinib. Invest New Drugs (2016) 0.77
MET exon 14 skipping defines a unique molecular class of non-small cell lung cancer. Oncotarget (2016) 0.77
MET Exon 14 Skipping in Non-Small Cell Lung Cancer. Oncologist (2016) 0.77
Sarcomatoid carcinoma of the stomach: A case report and literature review. Oncol Lett (2015) 0.76
Mutations at the splice sites of exon 14 of MET gene: a new target for sarcomatoid carcinomas? Ann Transl Med (2016) 0.76
MET Exon 14 Alterations in Lung Cancer: Exon Skipping Extends Half-Life. Clin Cancer Res (2016) 0.76
MET Inhibition in Clear Cell Renal Cell Carcinoma. J Cancer (2016) 0.76
Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes for Early Breast Cancer According to Disease Subtypes: Sensitivity Analysis of Randomized Trials in Adjuvant and Neoadjuvant Setting. Oncologist (2016) 0.80
Patients' perception of chemotherapy side effects: Expectations, doctor-patient communication and impact on quality of life - An Italian survey. Eur J Cancer Care (Engl) (2016) 0.75
Prognostic model for advanced breast carcinoma with luminal subtype and impact of hormonal maintenance: Implications for post-progression and conditional survival. Breast (2016) 0.75
Neoadjuvant Chemotherapy In Triple-Negative Breast Cancer: A Multicentric Retrospective Observational Study In Real-Life Setting. J Cell Physiol (2017) 0.75